Abstract | Many patients with malignant gliomas do not respond to alkylating agent chemotherapy. Alkylator resistance of glioma cells is mainly mediated by the DNA repair enzyme O 6 -methylguanine-DNA methyltransferase (MGMT). Epigenetic silencing of the MGMT gene by promoter methylation in glioma cells compromises this DNA repair mechanism and increases chemosensitivity. MGMT promoter methylation is, therefore, a strong prognostic biomarker in paediatric and adult patients with glioblastoma treated with temozolomide. Notably, elderly patients (>65-70 years) with glioblastoma whose tumours lack MGMT promoter methylation derive minimal benefit from such chemotherapy. Thus, MGMT promoter methylation status has become a frequently requested laboratory test in neuro-oncology. This Review presents current data on the prognostic and predictive relevance of MGMT testing, discusses clinical trials that have used MGMT status to select participants, evaluates known issues concerning the molecular testing procedure, and addresses the necessity for molecular-contextdependent interpretation of MGMT test results. Whether MGMT promoter methylation testing should be offered to all individuals with glioblastoma, or only to elderly patients and those in clinical trials, is also discussed. Justifications for withholding alkylating agent chemotherapy in patients with MGMT-unmethylated glioblastomas outside clinical trials, and the potential role for MGMT testing in other gliomas, are also discussed.
Introduction
Glioblastoma is the most common primary tumour of the CNS, and accounts for 12-15% of all intracranial tumours and 50-60% of gliomas. 1 Typically, patients diagnosed with glioblastoma die within a few months if untreated. Standard treatment-consisting of surgery followed by radiotherapy in addition to chemotherapy with the alky lating agent temozolomide-increases median survival to 12-15 months, although the disease typically progresses within 6-9 months, and 2-year survival is less than 25%. 2 The European Organization for Research and Treatment of Cancer (EORTC) 26981-22981-National Cancer Institute of Canada (NCIC) CE.3 randomized trial demonstrated that the survival benefit derived from combined radiotherapy and temozolomide chemotherapy is higher in patients whose tumours show methylation of the O 6 -methylguanine-DNA methyltransferase (MGMT) promoter than in those whose tumours have an unmethy lated MGMT promoter. 3 The value of MGMT promoter methylation for predicting a favourable response to alky lating chemotherapy has since been confirmed. 4 However, to date, MGMT biomarker assessment has not been introduced into routine clinical decision-making.
The prospect of stratifying patients in clinical trials according to their MGMT promoter methylation status has introduced major challenges for trial logistics, and raises key questions regarding the sensitivity and specificity of MGMT testing methods. In addition, it is difficult to define scientifically sound comparator (standard of care) arms for trials that group patients on the basis of their MGMT status. Although a small number of patients with glioblastoma might benefit from a combination of radiotherapy and temozolomide, despite having tumours that lack MGMT promoter methylation, the benefits of this therapy are limited in this group. 3 This observation highlights the necessity for different therapeutic approaches in patients with glioblastoma depending on their MGMT status. The primary unmet need in patients with MGMT-unmethylated glioblastomas is the identification of novel drugs that can provide a greater survival benefit than that associated with radiotherapy, either alone or in combination with temozolomide. Furthermore, several phase II and phase III clinical trials have assessed whether combinations of novel targeted compounds and radiotherapy (administered without temozolomide) are less toxic than if these compounds were added to radiotherapy plus temozolomide.
Key points
-methylguanine-DNA methyltransferase (MGMT) promoter methylation predicts responsiveness to alkylating chemotherapies in glioblastoma, but is not a prognostic biomarker in gliomas lacking isocitrate dehydrogenase gene mutations ■ Treatment decisions in elderly patients with glioblastoma should take MGMT promoter methylation status into account ■ MGMT testing to select patients with glioblastoma for clinical trials is feasible, and withholding temozolomide from patients without MGMT promoter methylation is justified in this context ■ MGMT-mediated resistance to alkylating chemotherapy is not overcome by alternative dosing schedules, but might be circumvented by the use of alternative treatments ■ Epigenetic inactivation of MGMT might facilitate the induction of point mutations in TP53 and other oncogenes during tumorigenesis and tumour progression ■ Quality-assured MGMT testing should be implemented as a molecular diagnostic method in the next WHO classification of brain tumours
In this Review, we discuss results from studies exploring the safety and efficacy of vascular endothelial growth factor (VEGF) inhibitors, [5] [6] [7] [8] the integrin inhibitor cilengitide, 9 ,10 the protein kinase C (PKC) inhibitor enzastaurin, 11 inhibitors of mammalian target of rapamycin (mTOR) such as temsirolimus, 12 and other agents. We will focus on the results of trials that have suggested two populations in whom MGMT testing could be introduced into daily clinical practice: elderly patients (older than 65-70 years) with glioblastoma plus comorbidities or reduction in their performance status, and patients who have anaplastic grade III gliomas without mutations in the isocitrate dehydrogenase 1 (IDH1) gene.
Glioblastoma therapy
The EORTC 26981-22981-NCIC CE.3 trial revealed that addition of temozolomide to standard radiotherapy was more beneficial in patients with glioblastomas that had MGMT promoter methylation than in patients with MGMT-unmethylated tumours. 3 A follow-up trial by the Radiation Therapy Oncology Group (RTOG0525) was based on the hypothesis that intensification of temozolomide therapy would sensitize MGMT-unmethylated tumours to alkylating DNA damage, thereby enhancing the effect of temozolomide. 13 The RTOG0525 trial, accordingly, compared the effects of intensive temozolomide maintenance therapy (28-day cycles of 21 days on treatment followed by 7 days off) after standard radiotherapy plus temozolomide with the standard maintenance regimen (5 consecutive days on treatment per 28-day cycle) on survival in patients with glioblastoma. Median overall survival for the trial cohort (n = 833) was 17.7 months, and median progression-free survival was 8.2 months. Although progression-free and overall survival rates did not differ between the groups receiving the standard and intensive temozolomide regimens (Table 1) , MGMT promoter methylation was identified as a prognostic marker: median overall survival in patients with MGMT-methylated tumours was 21.2 months, versus 14.0 months in patients whose tumours lacked MGMT promoter methylation. 14 In 2012, trials sponsored by the Neuro-oncology Working Group of the German Cancer Society and the Nordic Clinical Brain Tumour Study Group not only provided strong evidence that MGMT methylation status has a role in predicting treatment responses in elderly patients with glioblastoma, but also demonstrated how MGMT assessment can help in selection of an appropriate treatment strategy. These trials indicated that temozolomide monotherapy was at least as effective as radiotherapy alone for elderly patients with glioblastoma, and that median survival was higher in temozolomidetreated patients with MGMT-methylated glioblastoma than in the other groups (Table 2) . 15, 16 Consequently, elderly patients with glioblastoma are no longer commonly given combination treatment (radiotherapy with temozolomide, followed by temozolomide maintenance).
Treatment options for glioblastoma progression have not been standardized, and the use of lomustine or retreatment with temozolomide is common practice in countries without access to bevacizumab, which is approved for the treatment of recurrent glioblastoma in the USA and many other countries, but not the European Union. 5, 17 Except in multiple noncontrolled case series, [18] [19] [20] [21] [22] MGMT data are not available from patients receiving lomustine or temozo lomide to treat glio blastoma progression. Such testing could, however, be done on the primary tumour tissue obtained at the time of the original diagnosis, and would not necessitate a new biopsy or resection. 
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Function of MGMT
MGMT is a highly evolutionarily conserved and ubiquitously expressed enzyme involved in DNA repair. It counter acts the lethal effects of alkylating agents by removing alkyl adducts from the O 6 position of guanine, but is irreversibly inactivated by doing so-a process that is termed suicide inhibition. 24 The persistent O 6 -methylguanine adduct induced by DNA-alkylating agents (such as temozolomide and nitrosourea derivatives) causes base mispairing, which manifests as mismatch repair during DNA replication and, according to the futile repair hypothesis, ultimately induces cell cycle arrest and cell death. [25] [26] [27] [28] The methylation damage induced by alkylating agents can be reversed by MGMT. This DNA repair activity provides resistance against the cytotoxic effects of DNA-alkylating drugs, further demonstrated by small molecule inhibitors of MGMT that restore sensitivity to alkylating agents ( Figure 1) . 28 However, the cytotoxic activity of O 6 -alkylguanine also requires intact mismatch repair machinery (discussed further below).
Although many studies have shown that deficiency of MGMT can increase the sensitivity of high-grade gliomas to alkylating agents, [28] [29] [30] [31] tumours with low levels of MGMT expression can still exhibit resistance to these drugs. Therefore, other mechanisms might be involved in the resistance of some tumours to chemotherapy.
Regulation of MGMT
The MGMT gene is located on chromosome 10q26 and consists of five exons. A 5' CpG island of 762 bp, including 98 CpG dinucleotides, encompasses large parts of the promoter region and the first exon. Some researchers have conducted analyses to identify correlations between gene expression and methylation at individual CpG sites within this MGMT-associated CpG island. [32] [33] [34] [35] However, it is still not completely clear how many CpG sites (and which ones in particular) in the MGMT CpG island have to be methylated to cause transcriptional silen cing in primary tumour cells, and which demonstrate the best associ ations with treatment outcome and patient survival. In fact, each diagnostic methylation-specific assay (Table 3) , whether qualitative, semiquantitative or fully quanti tative, interro gates distinct sets of CpG sites within the MGMT CpG island. 36, 37 In addition to promoter methy lation, MGMT gene body methylation has been shown to be functionally relevant for differential MGMT protein levels in glioma biopsy samples, perhaps by regulating transcription of the gene. In glioma cells that lack MGMT promoter methylation but display gene body methy lation, sensitivity to temozolomide has been restored by decitabine demethylating treatment in vitro. 38 Expression of the MGMT protein can also be regulated by histone modifications and aberrant expression or dysfunction of transcriptional activators or repressors. Both increased methylation of histone H3 lysine 9 (H3K9) and binding of methyl-CpG binding protein 2 (MeCP2) to the MGMT promoter region were shown to be associated with promoter methylation and transcriptional down regulation, whereas histone H3K9 and H4K20 acetylation, and methylation of H3K4, were detected in MGMT-expressing cells. 33, 39 Increased acetylation of histone H3K9 and decreased dimethylation of this residue have been linked to MGMT upregulation and acquired resistance to temozolomide in glioblastoma cell lines. In line with these findings, treatment with histone deacetylase inhibitors potentiated the development of acquired temozolomide resistance in glioblastoma cells. 40 Various transcription factors enhance the activity of the MGMT promoter, including Sp1, 41 NF-κB, 42 the CBP-p300 transcriptional coactivator complex 43 and AP-1, 44 whereas cellular tumour antigen p53 has been implicated as a repressor of MGMT transcription. 45 Moreover, emerging evidence suggests that hypoxia might upregulate MGMT expression via hypoxia-inducible factor (HIF)-1α signalling, 46 which might contribute to temozolomide resistance 
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in glioma stem cells located, for example, in hypoxic perinecrotic niches. In turn, these cells might be sensitized to temozolomide by treatment with bone morphogenetic protein 2 (BMP2), which can downregulate HIF-1α-mediated MGMT induction. 47 Induction of temozo lomide resistance might also be conferred by expression of the hypoxia-inducible and steroid-inducible gene NDRG1, the protein product of which binds to-and thus probably sustains the action of-MGMT. 48 A further level of MGMT regulation might involve direct binding of specific microRNAs (miRNAs) to the 3' untranslated region of MGMT transcripts, which could lead to decreased mRNA stability and/or reduced protein translation. 49 Distinct miRNAs that have been implicated as direct regulators of MGMT expression include miR-181b, 50 ,51 miR-181d, 51 miR-221 and miR-222, 52 as well as miR-767-3p and miR-648. 49 Aberrant expression of these miRNAs might contribute to the variable MGMT expression observed in MGMT-unmethylated tumours ( Figure 2 ). However, the relative importance of these different regulatory systems in tumour responsiveness to temozolomide is not known.
Implications of MGMT methylation
The potential value of MGMT protein expression as a biomarker for treatment response was originally established in patients with malignant glioma, who seemed to derive considerably increased benefit from carmustine treatment when levels of MGMT in their tumours were low. 37, 53 Decreased expression of MGMT protein is mainly attributed to epigenetic silencing of the MGMT gene, mediated by promoter methylation. Correlations between MGMT promoter methylation and improved survival were first demonstrated in noncontrolled studies involving series of patients with glioma who were treated with nitrosoureas 29 or temozolomide. 54 Questions surrounding why MGMT becomes epigenetically silenced in subsets of glioma cells, and how this alteration might provide a tumour-promoting effect, have not been resolved completely. In gliomas with IDH1 and IDH2 mutations, MGMT is one of a set of genes that become methylated due to global changes in DNA methylation resulting from increased levels of 2-hydroxyglutarate, which is aberrantly produced by mutant forms of IDH1 or IDH2 enzymes. 55 In turn, 2-hydroxyglutarate inhibits various α-ketoglutarate-dependent enzymes, including TET hydroxylases and histone demethylases. 56 Inhibition of these enzymes leads to aberrant DNA and histone methy lation, which eventually results in increased methylation of CpG islands in glioma cells bearing IDH1 and IDH2 mutations. This methylator phenotype leads to epigenetic silencing of many different genes, including MGMT. 57, 58 The causes and molecular mechanisms of MGMT promoter methylation in gliomas with nonmutant IDH1 or IDH2, which includes approximately 40% of primary glioblastomas, are less clear. Functionally, MGMT promoter methylation and transcriptional silencing might not only decrease temozolomide resistance, but also increase genetic instability (which could promote tumori genesis), particularly by facilitating the appearance of G>A transition mutations. 59 This concept is supported by the observation that MGMT-deficient mice are more sensitive than wild type controls to cancer development following challenge with DNA-alkylating substances. 60 In addition, associations between MGMT promoter methylation and increased frequencies of G>A transition mutations in tumour suppressor genes (such as KRAS and the p53-encoding gene TP53) have been reported in various cancers, including gliomas. 59, 61, 62 These findings are corroborated in The Cancer Genome Atlas (TCGA) data set of glioblastomas, which also reveals increased frequencies of TP53 and PTEN point mutations in MGMTmethylated versus MGMT-unmethylated glioblastomas. 63 Moreover, treatment of MGMT-inactivated glioblastomas with temozolomide frequently induces a hypermutator phenotype, which might lead to secondary resistance by causing mutations in DNA mismatch repair genes. 63 Thus, epigenetic inactivation of MGMT might facilitate the induction of point mutations in TP53 and other genes during tumorigenesis and progression, and temozolomide treatment of such tumours could facilitate the emergence of secondary resistance to alkylating agents by indu cing inactivating mutations in mismatch repair genes. In line with this hypothesis, MGMT promoter methylation status is usually homogeneous within malignant gliomas, 64 which suggests that MGMT inactivation is an early event in glioma development, regardless of the presence of IDH1 or IDH2 mutations. Although acquired (somatic) MGMT mutations that reduce enzymatic activity have been reported in certain epithelial cancers, 65, 66 MGMT mutations only occur in 0.4% of malignant gliomas. 63 
MGMT promotor methylation testing
Standardized tests
The advantages and limitations of the most commonly used techniques for MGMT promoter methylation testing have been thoroughly reviewed elsewhere 28 and, consequently, are only briefly outlined here. To be suitable for both routine clinical practice and research use, a standardized MGMT test should be sensitive, specific, reproducible, and applicable to formalin-fixed and paraffin-embedded tissues. Methylation-specific PCR (MSP) has evolved into the most commonly used DNAbased diagnostic method for promoter methylation, owing to its simplicity and cost-effectiveness (Figure 3) . 67 MSP can be reliably performed on small stereotactic biopsy specimens, for example, from patients with nonresectable gliomas. 68 Moreover, MSP of serial stereotactic biopsy specimens has revealed a homogeneous distribution of MGMT promoter methylation in glioblastomas. 64 However, MSP cannot detect heterogeneous patterns of methylation, 69 especially when performed on low-quality DNA extracted from fixed and embedded tissue. 70, 71 Pyrosquencing overcomes this disadvantage, as it provides quantitative information on the extent of methylation at each individual CpG site sequenced; however, allele-specific information is lost in the process (Figure 4) . 60 Additional methods (Table 3) are based on MGMT mRNA expression analysis by quantitative reverse transcription PCR, 72 MGMT protein detection by immunohistochemistry or western blot analysis, 73, 74 and assessment of MGMT enzymatic activity. 75 However, assays based on expression analyses and determination of enzymatic activity are prone to contamination of tissue samples by non-neoplastic, MGMT-positive cells, which can give rise to false-positive results.
In prospective clinical trials, simple or quantitative MSP assays have been most commonly used (Tables 1,2 ). In the NOA-08 trial, 15 results obtained by quantitative MSP 76 and simple MSP 67 showed good concordance. However, the sensitivity and specificity of these assays for detecting promoter hypermethylation critically depends on the specific PCR protocols employed-different methods can yield slightly different results. The definition and prospective validation of reliable cut-off values for use in quantitative assays, such as quantitative MSP and pyrosquencing, require substantial resources, including expensive reagents and equipment. As a result, to date, only one quantitative MSP assay has been prospectively validated in a phase III trial for glioblastoma. zone' representing weakly or partly methy lated tumours that cannot be unequivocally assigned to either the methylated or unmethylated categ ory. This approach might be acceptable for clinical trials that employ MGMT methy lation status as an entry criterion, as such trials could simply exclude patients with 'grey zone' test results. However, it is hardly acceptable in routine clinical practice, as treatment decisions have to be made for every individual patient. One possible approach for clinical practice would be to re-evaluate tumours that demonstrate equivocal, borderline or grey zone results on one test-for example, MSPwith an independent analysis using a second method, such as pyrosquencing ( Figure 5) . If the independent method shows a clear-cut result, the tumour can be recateg orized accordingly. Although this approach may not provide an unequivocal result for all tumours, it may at least decrease the fraction of patients without a definitive test result.
Irrespective of the method applied, care should be taken to standardize diagnostic procedures and establish internal quality control measures. Moreover, we strongly recommend that each laboratory evaluates its own diagnostic performance through regular participation in external quality assessments, which are urgently needed to ensure the reproducibility and interlaboratory comparability of test results.
Quality control
As MGMT promoter methylation testing enters routine clinical practice, internal and external quality control measures need to be reinforced, as both false-positive and false-negative results could be harmful for patients. Internal quality control measures for diagnostic MGMT testing should include histological quality checks of tissue specimens, regular evaluations for reproducibility of test results, implementation of measures to both avoid and detect contamination, and guidelines for troubleshooting and data interpretation. Standardized operating procedures should also be established for the entire testing procedure.
Each tissue sample, which must not be derived from necrotic areas, needs to be histologically checked by macro dissection to ensure that it includes sufficient tumour cell content (≥80%) to avoid false-negative results. Repeated testing of the same specimen to ensure test reproducibility is recommended. To avoid crosscontamination, the use of contaminant-degrading reaction protocols and separate laboratory areas for pre-PCR and post-PCR procedures is mandatory. 71 Appropriate positive controls (for example, DNA that has been methylated in vitro, or DNA from a known MGMT-methylated tumour or cell line) and negative controls (MGMT-unmethylated DNA, or a no-template sample) should be run with each test. The results should be interpreted by experienced staff who are aware of the potential methodological pitfalls and appropriately trained in the troubleshooting thereof. As mentioned above, the use of a second, independent testing method to re-analyse samples with borderline results may be appropriate. The most commonly applied method of methylation analysis uses bisulphite conversion, in which treatment of DNA with bisulphite converts cytosine residues into uracil, but leaves 5-methylcytosine residues unaltered (1-2). Methylation-specific primer pairs (3) include sequences complementary to those containing only unconverted 5-methylcytosines. By contrast, non-methylation-specific primer pairs include sequences complementary to those in which unmethylated cytosines have been converted to thymines. Methylation status at a given site is determined by which specific primers achieve DNA amplification (4). *Treatment of DNA with bisulphite converts cytosine residues to uracil, but leaves 5-methylcytosine residues unaltered. Abbreviation: MSP, methylation-specific PCR. Modified from Wikipedia, 106 which is in the public domain.
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In addition to these internal considerations, external quality assessment (EQA) measures are becoming increasingly important. In 2012, the European Consensus Conference for EQA in molecular pathology 77 resulted in publication of guidelines for implementation of appropriate EQA schemes for predictive molecular tests for specific tumours, such as KRAS mutations in colon cancer, EGFR mutations and ALK rearrangements in non-smallcell lung cancer, 78 and BRAF mutations in melanoma. 79 Such EQA measures involve the implementation of centrally organized proficiency testing programmes in the form of standardized interlaboratory comparisons at the regional, national and international levels. These comparisons promote not only good laboratory practice, but also harmonization of molecular diagnostic testing across different laboratories. [78] [79] [80] In neuro-oncology, the first interlaboratory comparison of tests for IDH1 mutations in gliomas revealed that results were consistent for detection of IDH1 Arg132His mutations via immunohistochemistry, whereas IDH1 sequencing yielded inconsistent results in two of the six participating laboratories. 81 The results of a pilot study that compared protocols for the determination of MGMT status across 23 centres in Germany, Austria and the Netherlands have so far only been published in a conference abstract. 82 The overall concordance rate was good (with a few outliers) in patients whose tumours were either strongly methylated or completely lacked methylation, whereas results from tumours with partial or borderline methylation were highly variable across different laboratories. These data lend further support to the necessity of EQA measures for diagnostic MGMT testing. Participation in such studies should be strongly encouraged: their results would provide reassurance for laboratories showing good test performance, and identify laboratories with sub optimal performance. Underperforming laboratories would be prompted to either improve their procedures or withdraw this test from their catalogue. Figure 3) involves synthesizing the complementary strand, 1 bp at a time (1), and detecting which base was added at each step. The addition of one of the four deoxynucleoside triphosphates initiates addition of the next base pair. DNA polymerase incorporates the complementary deoxynucleoside triphosphates into the template, which leads to the stoichiometric release of pyrophosphate (2) . ATP sulphurylase converts pyrophosphate to ATP, and this ATP fuels the conversion of luciferin to oxyluciferin, which generates visible light (3). Thus, light is produced only when the added nucleotide complements the first unpaired base of the template. The sequence of added nucleotides that produces chemiluminescent signals enables determination of the sequence of the template strand (4). Unincorporated nucleotides and ATP are degraded by apyrase before the reaction is restarted by addition of the next nucleotide (5). *Treatment of DNA with bisulphite converts cytosine residues to uracil, but leaves 5-methylcytosine residues unaltered. Modified from Wikipedia, 106 which is in the public domain.
Prospects for biomarker-driven therapy
Owing to its good prognostic and predictive performance, assessment of MGMT methylation status has been incorporated into current and planned clinical trials in patients with glioma as a prognostic indicator, for risk stratification, 14 or even as a patient selection criter ion.
9-12 Additionally, MGMT testing is frequently requested in routine clinical work-up as a prognostic biomarker. Although assays for this molecular biomarker have existed for more than 10 years, they have only been included in clinical guidelines for neuro-oncology in the past 4 years. 83 Arguments against the clinical use of such test ing for patient stratification include the technical challenges associated with methylation testing-including the grey zone problem-and, more importantly, the lack of evidence-based alternatives to the current standard of care in glioblastoma. In a patient whose tumour lacks MGMT promoter methylation, the prospect of offering radiotherapy alone is unappealing, considering the limited efficacy of this approach. From this patient's point of view, even if the possibility of improved survival following combined radiotherapy and temozolomide is small, this treatment might be worth trying, particularly given the generally favourable safety and tolerability profile of temozolomide. 84 From clinician and caregiver perspectives, however, such testing is difficult to justify if each patient is offered the same treatment anyway.
Trials in unmethylated glioblastoma
Several novel therapies have been investigated as potential replacements for temozolomide in patients with MGMTunmethylated glioblastomas (Table 4) . To date, however, drug development strategies have focused not on development of targeted treatments specifically for patients with MGMT-unmethylated glioblastomas-for example, by selecting appropriate alternative molecular markers-but, rather, on simply avoiding substrates of MGMT.
The main advantages of conducting therapeutic trials of alternatives to temozolomide in patients with MGMT-unmethylated tumours are the opportunity to analyse interactions of the experimental compound with radiotherapy alone (and, hence, potential detection of radiosensitization), the potential limitation of adverse effects resulting from omission of temozolomide, and enrichment of the patient population studied. The biggest challenges in the design of these trials have included selection of an appropriate molecular testing procedure, choosing rational and hypothesis-driven agent(s) for the experimental treatment, and defining the protocol used for the standard treatment.
Investigators have typically chosen radiotherapy combined with temozolomide rather than radiotherapy alone as the standard therapy. The motivation for this choice is probably mitigation of the risk of false-negative test results, or of undertreating the rare patients with MGMT-unmethylated tumours who might still benefit from temozolomide. So far, therefore, such trials have been feasible only in Europe; they cannot be performed in the USA because nonadherence to standard-of-care guidelines is not permitted.
Alternatives to temozolomide
The first trial that restricted patient entry according to MGMT promoter methylation status was S039 (Table 4) , which tested the PKC-β inhibitor enzastaurin added to radiotherapy in patients with newly diagnosed MGMTunmethylated glioblastoma. This single-group, phase II trial set the primary efficacy end point as 6 months' progression-free survival in 55% of patients.
11 By contrast, in the EORTC 26981-22981-NCIC CE.3 trial (which compared radiotherapy with and without temozolomide in patients with newly diagnosed glioblastoma), only 40% of patients with MGMT-unmethylated glioblastoma achieved 6 months' progression-free survival in the radiotherapy plus temozolomide arm. Although the S039 trial generated some interesting data, and demonstrated that multicentre clinical trials with biomarkerdefined entry criteria are feasible, this study failed to meet its pre defined efficacy end point and was hindered by the lack of a control arm.
11 However, the results of S039 also suggested that omission of temozolomide in this population of patients may be ethically justified, because no evidence of undertreatment of these patients was foundtreatment efficacy in the temozolomide-free arm was comparable to that in the standard-of-care arm. 3, 11 The GLARIUS trial replaced temozolomide with a combination of bevacizumab and irinotecan plus radiotherapy as first-line treatment for patients with MGMT-unmethylated glioblastoma. The results of this randomized, multicentre, phase II study demonstrated improved progression-free survival at 6 months in the bevacizumab and irinotecan arm versus standard care (78% versus 41%). Despite the challenge of using radiographic measures to define progression, this is the first trial thus far to report efficacy of an alternative chemotherapeutic agent added to radiotherapy to treat patients with newly diagnosed glioblastoma without hypermethylation of the MGMT promoter, although the overall survival benefit suggested from the preliminary data was not maintained at final analysis. 8 In the EORTC 26082 trial, the mTOR inhibitor temsirolimus replaced temozolomide in patients with newly diagnosed MGMT-unmethylated glioblastoma. Data from this phase II randomized controlled trial, which completed accrual of patients in 2012, have been published in an abstract (Table 4) . 12 Clearly, the poor prognosis of patients with MGMTunmethylated gliomas should stimulate more research activities in this population. We expect that more therapeutic strategies will be developed in the future that demonstrate survival benefits superior to those associated with temozolomide plus radiotherapy in patients with MGMT-unmethylated glioma. Leaving out temozolomide, these therapies might combine more than one MGMT-independent regimen, or use more than one molecular biomarker.
Additions to temozolomide
A slightly different approach has been adopted in the CORE study, a formal companion to the CENTRIC trial. Here, the integrin inhibitor cilengitide was added to temozo lomide plus radiotherapy, rather than replacing the alkylating agent in patients with MGMT-unmethylated glioblastoma.
10 This phase II randomized controlled trial had a three-arm design: patients received standard care, or radiotherapy with temozolomide plus cilengitide (administered at two different dosing schedules). Although the study reported negative results, the group given radiotherapy with temozolomide plus cilengitide twice weekly showed an intriguing improvement in overall survival: 16.3 months, compared with 13.4 months in the control arm and 14.5 months in the intensified cilengitide treatment arm. This result is comparable to the overall survival of 16.6 months in the group given radiotherapy with bevacizumab and irinotecan in the GLARIUS trial. 8 Only one completed trial, the CENTRIC trial, has specifically included patients with newly diagnosed, MGMT-methylated glioblastoma. In this multicentre phase III study, patients with MGMT-methylated glioblastoma were randomly assigned to receive either standard radiotherapy and temozolomide, or radiotherapy and temozolomide plus cilengitide (twice per week). The primary end point was not met, despite an encouraging median overall survival of 26 months, as there was no difference between the treatment arms in any of the parameters analysed.
9
Trials in elderly patients Since the release of the initial data from the EORTC 26981-22981-NCIC CE.3 trial, 3 debate has been ongoing in relation to whether MGMT promoter methylation in glioblastoma is merely a prognostic marker, or whether it is both predictive and prognostic. As the RTOG0525 trial did not contain a temozolomide-free control group, it was designed only to confirm a prognostic role for MGMT promoter methylation, which was convincingly shown (Table 1). 14 An important role for MGMT testing in elderly patients with glioblastoma had already been suggested by the results of the nonrandomized ANOCEF trial 85 and a prospective cohort study conducted by the German Glioma Network. 86 Subsequently, data from biomarker-defined subgroup analyses in two randomized trials, both of which included first-line treatment consisting of either radiotherapy alone or temozolomide chemotherapy alone (but not the combination of both), defined a predictive role of MGMT promoter methylation for response to temozolomide chemotherapy. 15, 16 These trials support the use of MGMT promoter methylation testing in the clinical assessment of elderly patients with glioblastoma.
In the NOA-08 trial, progression-free survival was longer in patients with MGMT promoter-methylated tumours who received dose-intensified temozolomide alone than in those who underwent radiotherapy alone, whereas the opposite was true for patients with MGMTunmethylated tumours. 15 Data for overall survival showed the same trend, but the difference between the two groups was not significant. 15 The Nordic trial showed prolonged overall survival in patients with MGMT-methylated glioblastoma who received temozolomide only, compared with those who underwent radiotherapy-only regimens (9.7 months versus 8.2 months). 16 However, overall survival for patients whose tumours lacked MGMT promoter methylation was similar in both treatment arms (6.8 months versus 7.0 months). 16 Of note, more patients switched from radiotherapy to temozolomide than from temozolomide to radiotherapy after progression (58.5% versus 46.1%) in the NOA-08 trial, and it is tempting to speculate that this disparity diluted the overall survival differences.
The evidence increasingly suggests that fundamental molecular differences are seen between malignant gliomas in patients of different age groups. Deletions of PTEN, amplification of EGFR and mutations in TP53, EGFRvIII, and IDH1 are differentially distributed among glioblastomas in young adults (19-40 years of age) versus patients older than 40 years. 86, 87 In multiple studies, 15, 86, 88 IDH mutations have rarely been observed in patients with malignant gliomas above the age of 60 years. A lack of IDH mutations (which confer the prognostically favourable glioma CpG island hypermethylator phenotype) 58 might contribute to the poor prognosis of elderly patients. By contrast, the distribution of MGMT promoter methy lation in primary glio blastomas without IDH1 or IDH2 mutations does not seem to vary with age. 87 The absence of other, as yet unknown, positive prognostic factors might enable the predictive properties of MGMT methylation to be singled out in this population.
MGMT testing outside glioblastoma
Support for a differential role for MGMT promoter methylation, depending on the context of IDH mutation status, in determining response to treatment comes from a retrospective analysis of anaplastic gliomas. In NOA-04 and EORTC 26951, 89, 90 MGMT promoter methylation was a prognostic marker of improved outcome, regardless of treatment with alkylating chemotherapy or radiotherapy, but did not predict the response to treatment. Among the potential explanations for these observations was a confounding influence of IDH1 and IDH2 mutations. 91 Mutations in these genes represent the most obvious difference between glioblastoma and WHO grade II and III gliomas: these mutations are seen in 50-70% of diffuse and anaplastic grade II and III gliomas and secondary glioblastomas, but only in 5-10% of primary glioblastomas from younger patients (aged 18-60 years), and almost never in glioblastomas from elderly patients. 88, 92 A retrospective analysis of subgroup data from the NOA-04 trial suggested a simple interaction model to explain the prognostic versus predictive relevance of MGMT status in grade III and grade IV gliomas. MGMT promoter methylation is a prognostic indicator for survival and time to treatment failure in patients with gliomas bearing IDH1 or IDH2 mutations, which represent the majority of grade III gliomas. In patients with gliomas that lack IDH1 or IDH2 mutations, hypermethylation of the MGMT promoter is predictive of a favourable response to alkylating chemotherapy. This model explains both the mainly prognostic role of MGMT methylation status in young patients with anaplastic gliomas or glioblastomas with IDH1 or IDH2 mutations, and the predictive role of MGMT methylation status in elderly patients with glioblastoma lacking IDH1 or IDH2 mutations. 93 The EORTC 26951 results also provide some evidence for this interaction, but the numbers of patients with tumours bearing IDH1 or IDH2 mutations were not sufficient to definitively answer this question. Additionally, this trial showed that determination of MGMT methylation status at two particular CpG sites (Table 3) 70 was of utmost relevance for predicting the response to (mainly alkylating and methylating) chemotherapy consisting of procarbazine, lomustine and vincristine ( Figure 6 ). 94 
Conclusions
In neuro-oncology, the role of molecular biomarkers is currently in transition from primarily research-oriented investigations towards routine clinical applications. As outlined in this Review, MGMT promoter methy lation status has already entered clinical guidelines as a predictive biomarker for elderly patients with glioblastoma. 15, 16, 83 In addition, the results of MGMT methylation testing might contribute to treatment decision-making in patients with anaplastic gliomas that lack IDH1 or IDH2 mutations. 93 However, the relevance of conducting parallel analyses of MGMT mRNA and protein expression is still under debate.
To extend the role of MGMT testing further, all future clinical trials involving alkylating chemotherapy should assess MGMT methylation status, and include it as a patient-stratification parameter. Concomitant assessment of MGMT promoter methylation status by several different methods, such as MSP and pyrosequencing, as well as critical assessment and reporting of biomarker data, 95, 96 is also encouraged. The lack of widespread adoption of MGMT testing is in part due to limitations associated with the available assays and procedures, and the lack of attractive therapeutic alternatives to the current standard of care. Another key factor might be the grim prognosis of the disease overall, regardless of MGMT status, which makes approaches that reduce the intensity of treatment seem less attractive. Thus, at many institutions, the scientific evidence supporting MGMT methylation status as a useful predictive biomarker has not yet been incorporated into the day-to-day clinical management of patients with glioma. In most European Union trial centres, withholding of temozolomide from patients with newly diagnosed glioblastoma without MGMT promoter methylation is considered justifiable in the context of clinical trials. This approach has already been used in three phase II studies led by the EORTC, industry and other study groups in Europe, 9-12 although only one of these three trials has generated clinically relevant data for patients with MGMT-unmethylated glioblastoma. 12 The general consensus that treatment decisions outside clinical trials should not be based on MGMT status is shifting, as many centres now recognize that testing is relevant in some circumstances. In particular, MGMT testing is helpful in elderly patients with glioblastoma to determine who should be treated with alky lating chemotherapy and who should receive radiotherapy. The question of whether alkylating chemotherapy should be combined with radiotherapy in elderly patients with MGMT-unmethylated tumours remains to be addressed in future studies. However, molecular techniques are continuing to evolve, and the relevance of defining clinically relevant subgroups of patients in different age groups remains to be established.
Next-generation sequencing techniques and microarray-based approaches, which are easier to standardize and less subject to bias than conventional PCR and methylation-specific multiplex ligation-dependent probe amplification, are becoming more widely available.
Integrative high-throughput analyses of protein, genetic and epigenetic marker profiles have already demonstrated the value of these markers in subclassification of various types of brain tumours, including glioblastomas, and these subgroups seem to have some prognostic relevance. 92, 97 However, whether these approaches have predictive as well as prognostic implications is as yet unknown. Assessments of single biomarkers, such as MGMT methylation testing, might eventually be replaced by comprehensive assessments of multiple genetic and epigenetic markers. Interpretation of the results from these new assays might, however, require dedicated staff with expertise in bioinformatics and stat istics. In the meantime, the issues relevant to routine MGMT testing will remain similar to those outlined in this Review, comprising the availability and reliability of testing procedures, applicability to routinely processed tissue specimens, establishment of internal and external quality control measures, cost-effectiveness, and speed of testing.
The most recent (2007) WHO classification of glioblastomas and anaplastic gliomas does not consider MGMT testing. Debate is ongoing about the clinical relevance of MGMT testing, and whether MGMT promoter methylation status should be incorporated into the next revision of the WHO classification. If so, a prerequisite would be that the recommended molecular analysis method should be available worldwide, affordable and easy to perform, and should not require equipment or consumables beyond those present in most medical laboratories. MSP satisfies these conditions, but other approaches are not necessarily excluded. In addition to inclusion of molecular testing in the WHO classification, national and international treatment guidelines for patients with malignant gliomas need to be amended to include molecular testing for the purposes of treatment stratification. These guidelines would be important for establishing appropriate care provision and reimbursement policies for new, clinically relevant molecular tests, which in most countries are currently not considered in health care and insurance systems.
Review criteria
Papers in the PubMed database published between January 1995 and November 2013, and abstracts published up to May 2014, were identified using the search terms "glioblastoma", "glioma", "MGMT", "integrin", "mTOR" and "PKC". Only papers published in English were reviewed. Relevant clinical trials were identified by searching http://www.clinicaltrials.gov using the search terms "glioblastoma" and "glioma".
